Lite Strategy (LITS) AI Stock Analysis

• Market Cap: $52.58M
• Dividend Yield: N/A
• Average Volume (3M): 622.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.75
• Revenue Growth: N/A
• EPS Growth: 81.20%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 36,769,676
• 10 Day Avg. Volume: 591,066
• 30 Day Avg. Volume: 622,792
• PEG Ratio: <0.01
• Price to Book (P/B): 1.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.45
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -16.82
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $1.50 ▲(12.78% Upside)

The score is held down primarily by weak and inconsistent financial performance (notably the 2025 revenue collapse and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). A debt-light balance sheet and positive corporate actions (CEO appointment and buyback) provide some support, while valuation is difficult to assess due to losses and no dividend.

Lite Strategy Business Overview & Revenue Model

Company Description

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

How the Company Makes Money

MEI Pharma makes money primarily through the development and commercialization of its oncology drug candidates. The company generates revenue from licensing agreements, milestone payments, and potential royalties related to the commercialization of its drug candidates. These agreements are often formed with larger pharmaceutical companies that have the resources to bring a drug to market. MEI Pharma's business strategy also involves strategic partnerships and collaborations that can provide funding and expertise for the continued development of its pipeline products. Additionally, the company may receive funding from government grants or research organizations to support its clinical trials and research activities.

Lite Strategy Financial Statement Overview

Summary

MEI Pharma faces significant financial challenges, particularly with revenue generation and profitability. The balance sheet shows limited leverage risks but declining asset base and equity levels. Cash flow issues highlight the need for operational efficiency improvements. The company's financial health is fragile, emphasizing the need for strategic adjustments to stabilize and grow.

Income Statement

The company shows volatility in revenue streams, with the latest TTM period reporting no revenue. The gross profit margin is negative due to a lack of revenue, and the TTM net profit margin is also negative, indicating a lack of profitability. Historical data shows fluctuating revenues with periods of positive EBIT and EBITDA margins, but the recent trend is concerning.

Balance Sheet

The balance sheet reveals a low debt burden, with a debt-to-equity ratio of 0, indicating no leverage risk. However, the equity ratio is declining, suggesting weakened financial stability. There is positive stockholders' equity, but the overall asset base has diminished over recent periods, raising concerns about resource sustainability.

Cash Flow

The cash flow statement highlights challenges in generating positive operating cash flow, which remains negative. The free cash flow is negative in the latest period, with the operating cash flow to net income ratio indicating inefficiencies. Prior periods show some positive cash flow from investing activities, but sustainability remains uncertain.

Breakdown	TTM	Dec 2025	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	0.00	0.00	65.30M	48.82M	40.70M
Gross Profit	0.00	-368.00K	-368.00K	65.30M	48.82M	40.70M
EBITDA	-3.64M	-17.09M	-17.09M	25.82M	-36.38M	-75.16M
Net Income	-3.64M	-15.95M	-15.95M	17.78M	-31.84M	-54.45M
Balance Sheet
Total Assets	113.34M	18.29M	18.29M	41.38M	120.81M	177.84M
Cash, Cash Equivalents and Short-Term Investments	10.11M	18.01M	18.01M	38.34M	100.69M	153.25M
Total Debt	0.00	0.00	0.00	0.00	12.73M	9.64M
Total Liabilities	1.07M	1.35M	1.35M	8.36M	96.19M	125.43M
Stockholders Equity	112.27M	16.93M	16.93M	33.02M	24.62M	52.41M
Cash Flow
Free Cash Flow	-4.51M	-20.84M	-20.84M	-50.48M	-52.52M	-49.23M
Operating Cash Flow	-4.51M	-20.84M	-20.84M	-50.47M	-52.48M	-48.75M
Investing Cash Flow	-100.00M	35.15M	35.15M	49.14M	53.69M	6.89M
Financing Cash Flow	96.61M	0.00	0.00	-11.87M	-40.00K	49.05M

Lite Strategy Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LITS, the sentiment is Negative. The current price of 1.33 is below the 20-day moving average (MA) of 1.43, below the 50-day MA of 1.66, and below the 200-day MA of 2.66, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 44.43 is Neutral, neither overbought nor oversold. The STOCH value of 31.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LITS.

Lite Strategy Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JSPR	52 Neutral	$42.82M	-0.26	-191.12%	―	―	-24.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LITS	47 Neutral	$52.58M	-1.09	-16.88%	―	―	81.20%
PRLD	47 Neutral	$102.47M	-1.12	-103.99%	―	250.00%	15.15%
GANX	46 Neutral	$69.62M	-2.83	-261.72%	―	―	42.29%
ABVC	44 Neutral	$49.09M	-9.05	-40.32%	―	56.52%	75.22%

Lite Strategy Corporate Events

Lite Strategy Finalizes New CEO Employment Agreement Terms

On November 14, 2025, Lite Strategy, Inc. appointed Justin J. File as Chief Executive Officer, adding to his existing roles as Chief Financial Officer and Secretary, and on December 23, 2025, the company executed a new employment agreement with him that is effective as of his CEO appointment date and replaces his prior contract. The 2025 employment agreement sets Mr. File’s base salary at $575,000 from October 1, 2025, provides a target annual bonus equal to 50% of base salary starting with the fiscal year beginning July 1, 2025, and confirms his eligibility for standard executive benefits and equity awards, while also detailing severance protections, COBRA reimbursements, pro‑rated bonus, and accelerated or full vesting of stock options in certain termination and change‑in‑control scenarios; he also signed a new proprietary information and inventions agreement replacing his earlier confidentiality arrangement.

Lite Strategy Appoints Justin J. File as CEO

On November 14, 2025, Lite Strategy, Inc. appointed Justin J. File as the permanent Chief Executive Officer and a member of the Board, following his previous role as Acting CEO. This appointment includes granting Mr. File options to purchase 635,000 shares of the company’s common stock, with vesting over 36 months, reflecting the company’s confidence in his leadership and strategic direction.

Lite Strategy Announces $25 Million Stock Buyback

On October 24, 2025, Dr. Thomas C. Reynolds announced his resignation from the board of directors of Lite Strategy, Inc., effective November 4, 2025, with no disagreements cited regarding company operations. On October 29, 2025, Lite Strategy announced a $25 million stock repurchase program, aiming to enhance shareholder value by buying back shares under favorable market conditions, signaling a strategic shift towards active capital market operations.